Showing results (31-40 of 125) with videos related to

Sort By:
Pageof 13
Plos One|July 21, 2017
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancerTomas Pascual, María Apellániz-Ruiz, Cristina Pernaut, et al.
Breast (Edinburgh, Scotland)|May 21, 2024
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper"Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, et al.
Medical Oncology (Northwood, London, England)|June 11, 2011
Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic functionBeatriz Pardo, Ramón Salazar, Eva Ciruelos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumorsBeatriz Pardo, Luis Paz-Ares, Josep Tabernero, et al.
Cancer Treatment Reviews|November 24, 2024
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancerRupert Bartsch, David Cameron, Eva Ciruelos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOXavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2013
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in SpainEmilio Alba, Eva Ciruelos, Rafael López, et al.
The Oncologist|January 26, 2019
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2Aleix Prat, Jan Christoph Brase, Yuan Cheng, et al.
Oncotarget|June 25, 2020
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET studySilvia P Corona, Fabiola Giudici, Guy Jerusalem, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Pageof 13